roma pharmaceuticals limited Company Information
Company Number
10217518
Next Accounts
Mar 2026
Shareholders
mark cresswell
roland alexander brown
View AllGroup Structure
View All
Industry
Manufacture of pharmaceutical preparations
Registered Address
ground floor, gibraltar house, crown square, first avenue, burton-on-trent, DE14 2WE
Website
romapharma.co.ukroma pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of ROMA PHARMACEUTICALS LIMITED at £7.6m based on a Turnover of £5.3m and 1.42x industry multiple (adjusted for size and gross margin).
roma pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of ROMA PHARMACEUTICALS LIMITED at £7.5m based on an EBITDA of £1.3m and a 5.9x industry multiple (adjusted for size and gross margin).
roma pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of ROMA PHARMACEUTICALS LIMITED at £0 based on Net Assets of £-1.5m and 2.07x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Roma Pharmaceuticals Limited Overview
Roma Pharmaceuticals Limited is a live company located in burton-on-trent, DE14 2WE with a Companies House number of 10217518. It operates in the manufacture of pharmaceutical preparations sector, SIC Code 21200. Founded in June 2016, it's largest shareholder is mark cresswell with a 45.9% stake. Roma Pharmaceuticals Limited is a young, mid sized company, Pomanda has estimated its turnover at £5.3m with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Roma Pharmaceuticals Limited Health Check
Pomanda's financial health check has awarded Roma Pharmaceuticals Limited a 4 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 5 areas for improvement. Company Health Check FAQs
4 Strong
3 Regular
5 Weak
Size
annual sales of £5.3m, make it smaller than the average company (£36m)
- Roma Pharmaceuticals Limited
£36m - Industry AVG
Growth
3 year (CAGR) sales growth of 79%, show it is growing at a faster rate (3.8%)
- Roma Pharmaceuticals Limited
3.8% - Industry AVG
Production
with a gross margin of 31%, this company has a comparable cost of product (31%)
- Roma Pharmaceuticals Limited
31% - Industry AVG
Profitability
an operating margin of 23.7% make it more profitable than the average company (8.4%)
- Roma Pharmaceuticals Limited
8.4% - Industry AVG
Employees
with 8 employees, this is below the industry average (93)
8 - Roma Pharmaceuticals Limited
93 - Industry AVG
Pay Structure
on an average salary of £67.9k, the company has an equivalent pay structure (£67.9k)
- Roma Pharmaceuticals Limited
£67.9k - Industry AVG
Efficiency
resulting in sales per employee of £665.6k, this is more efficient (£373.3k)
- Roma Pharmaceuticals Limited
£373.3k - Industry AVG
Debtor Days
it gets paid by customers after 75 days, this is later than average (46 days)
- Roma Pharmaceuticals Limited
46 days - Industry AVG
Creditor Days
its suppliers are paid after 67 days, this is slower than average (35 days)
- Roma Pharmaceuticals Limited
35 days - Industry AVG
Stock Days
it holds stock equivalent to 110 days, this is in line with average (115 days)
- Roma Pharmaceuticals Limited
115 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 7 weeks, this is less cash available to meet short term requirements (10 weeks)
7 weeks - Roma Pharmaceuticals Limited
10 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 146.3%, this is a higher level of debt than the average (44.3%)
146.3% - Roma Pharmaceuticals Limited
44.3% - Industry AVG
ROMA PHARMACEUTICALS LIMITED financials
Roma Pharmaceuticals Limited's latest turnover from June 2024 is estimated at £5.3 million and the company has net assets of -£1.5 million. According to their latest financial statements, Roma Pharmaceuticals Limited has 8 employees and maintains cash reserves of £704.6 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | |
---|---|---|---|---|---|---|---|---|
Turnover | ||||||||
Other Income Or Grants | ||||||||
Cost Of Sales | ||||||||
Gross Profit | ||||||||
Admin Expenses | ||||||||
Operating Profit | ||||||||
Interest Payable | ||||||||
Interest Receivable | ||||||||
Pre-Tax Profit | ||||||||
Tax | ||||||||
Profit After Tax | ||||||||
Dividends Paid | ||||||||
Retained Profit | ||||||||
Employee Costs | ||||||||
Number Of Employees | 8 | 7 | 7 | 6 | 4 | 2 | 2 | 2 |
EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | |
---|---|---|---|---|---|---|---|---|
Tangible Assets | 6,498 | 8,293 | 12,816 | 20,620 | 12,468 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Fixed Assets | 6,498 | 8,293 | 12,816 | 20,620 | 12,468 | 0 | 0 | 0 |
Stock & work in progress | 1,109,016 | 695,138 | 448,504 | 180,482 | 0 | 0 | 0 | 0 |
Trade Debtors | 1,106,966 | 905,628 | 353,723 | 92,980 | 39,575 | 0 | 473,433 | 871,358 |
Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Misc Debtors | 207,205 | 232,971 | 339,350 | 223,209 | 139,287 | 96,029 | 0 | 0 |
Cash | 704,550 | 310,122 | 124,551 | 376,833 | 284,868 | 410,875 | 0 | 0 |
misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total current assets | 3,127,737 | 2,143,859 | 1,266,128 | 873,504 | 463,730 | 506,904 | 473,433 | 871,358 |
total assets | 3,134,235 | 2,152,152 | 1,278,944 | 894,124 | 476,198 | 506,904 | 473,433 | 871,358 |
Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Creditors | 683,513 | 551,946 | 340,642 | 173,796 | 9,890 | 0 | 1,532,578 | 1,500 |
Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,012,776 |
other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other current liabilities | 3,901,074 | 4,031,925 | 3,933,296 | 3,240,561 | 2,767,545 | 2,551,574 | 0 | 0 |
total current liabilities | 4,584,587 | 4,583,871 | 4,273,938 | 3,414,357 | 2,777,435 | 2,551,574 | 1,532,578 | 1,014,276 |
loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 1,500 | 0 |
other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 1,500 | 0 |
total liabilities | 4,584,587 | 4,583,871 | 4,273,938 | 3,414,357 | 2,777,435 | 2,551,574 | 1,534,078 | 1,014,276 |
net assets | -1,450,352 | -2,431,719 | -2,994,994 | -2,520,233 | -2,301,237 | -2,044,670 | -1,060,645 | -142,918 |
total shareholders funds | -1,450,352 | -2,431,719 | -2,994,994 | -2,520,233 | -2,301,237 | -2,044,670 | -1,060,645 | -142,918 |
Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | |
---|---|---|---|---|---|---|---|---|
Operating Activities | ||||||||
Operating Profit | ||||||||
Depreciation | 5,714 | 7,059 | 9,919 | 6,458 | 3,707 | 0 | 0 | 0 |
Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax | ||||||||
Stock | 413,878 | 246,634 | 268,022 | 180,482 | 0 | 0 | 0 | 0 |
Debtors | 175,572 | 445,526 | 376,884 | 137,327 | 82,833 | -377,404 | -397,925 | 871,358 |
Creditors | 131,567 | 211,304 | 166,846 | 163,906 | 9,890 | -1,532,578 | 1,531,078 | 1,500 |
Accruals and Deferred Income | -130,851 | 98,629 | 692,735 | 473,016 | 215,971 | 2,550,074 | 1,500 | 0 |
Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash flow from operations | ||||||||
Investing Activities | ||||||||
capital expenditure | ||||||||
Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
cash flow from investments | ||||||||
Financing Activities | ||||||||
Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | -1,012,776 | 1,012,776 |
Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
share issue | ||||||||
interest | ||||||||
cash flow from financing | ||||||||
cash and cash equivalents | ||||||||
cash | 394,428 | 185,571 | -252,282 | 91,965 | -126,007 | 410,875 | 0 | 0 |
overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
change in cash | 394,428 | 185,571 | -252,282 | 91,965 | -126,007 | 410,875 | 0 | 0 |
roma pharmaceuticals limited Credit Report and Business Information
Roma Pharmaceuticals Limited Competitor Analysis
Perform a competitor analysis for roma pharmaceuticals limited by selecting its closest rivals, whether from the MANUFACTURING sector, other mid companies, companies in DE14 area or any other competitors across 12 key performance metrics.
roma pharmaceuticals limited Ownership
ROMA PHARMACEUTICALS LIMITED group structure
Roma Pharmaceuticals Limited has no subsidiary companies.
Ultimate parent company
ROMA PHARMACEUTICALS LIMITED
10217518
roma pharmaceuticals limited directors
Roma Pharmaceuticals Limited currently has 4 directors. The longest serving directors include Mr Mark Cresswell (Jun 2016) and Mr Roland Brown (Jun 2016).
officer | country | age | start | end | role |
---|---|---|---|---|---|
Mr Mark Cresswell | England | 57 years | Jun 2016 | - | Director |
Mr Roland Brown | England | 53 years | Jun 2016 | - | Director |
Mr Philip Wright | England | 59 years | Jun 2020 | - | Director |
Ms Lucy Walley | England | 44 years | Jun 2024 | - | Director |
P&L
June 2024turnover
5.3m
+47%
operating profit
1.3m
0%
gross margin
31%
-11.26%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
June 2024net assets
-1.5m
-0.4%
total assets
3.1m
+0.46%
cash
704.6k
+1.27%
net assets
Total assets minus all liabilities
roma pharmaceuticals limited company details
company number
10217518
Type
Private limited with Share Capital
industry
21200 - Manufacture of pharmaceutical preparations
incorporation date
June 2016
age
9
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
June 2024
previous names
N/A
accountant
ATRAXA CONSULTING LIMITED
auditor
-
address
ground floor, gibraltar house, crown square, first avenue, burton-on-trent, DE14 2WE
Bank
-
Legal Advisor
-
roma pharmaceuticals limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 2 charges/mortgages relating to roma pharmaceuticals limited. Currently there are 1 open charges and 1 have been satisfied in the past.
roma pharmaceuticals limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for ROMA PHARMACEUTICALS LIMITED. This can take several minutes, an email will notify you when this has completed.
roma pharmaceuticals limited Companies House Filings - See Documents
date | description | view/download |
---|